TE
$72.50
+0.02
(+0.03%)
As of Oct 15, 2026, 1:37 AM EDT
Price history
Bio-Techne (TECH) is trading up at $72.50 (+0.03%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Bio-Techne revenue & net income history (FY2017–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Growth (year over year) | +12.8% | +14.2% | +11.0% | +3.5% | +26.0% | +18.7% | +2.8% | +2.0% | +5.2% | −0.4% |
| Gross profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Gross margin | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating income | $120.6M | $136.2M | $146.7M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Operating margin | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net income | $76.1M | $126.2M | $96.1M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M | $181.8M |
| Net margin | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (diluted) | $0.51 | $0.83 | $0.62 | $1.46 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Balance sheet | ||||||||||
| Cash and equivalents | $91.6M | $122.0M | $100.9M | $146.6M | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Total assets | $1.56B | $1.59B | $1.88B | $2.03B | $2.26B | $2.29B | $2.64B | $2.70B | $2.56B | $2.59B |
| Total liabilities | $608.6M | $514.1M | $718.8M | $646.4M | $691.7M | $593.8M | $672.2M | $635.0M | $639.1M | $478.5M |
| Long-term debt | $343.8M | $339.0M | $492.7M | $344.2M | $328.8M | $243.4M | $350.0M | $319.0M | $346.0M | $200.0M |
| Shareholders' equity | $949.6M | $1.08B | $1.17B | $1.38B | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
| Cash flow | ||||||||||
| Operating cash flow | $143.7M | $170.4M | $181.6M | $205.2M | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M | $292.1M |
| Capital expenditure | $15.2M | $20.9M | $25.4M | $51.7M | $44.3M | $44.9M | $38.2M | $62.9M | $31.0M | $28.9M |
| Free cash flow | $128.5M | $149.4M | $156.2M | $153.5M | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
| Dividends paid | $47.3M | $48.0M | $48.4M | $48.9M | $49.6M | $50.2M | $50.3M | $50.4M | $50.4M | $49.9M |
| Share buybacks | — | $0 | $15.4M | $50.1M | $43.2M | $160.9M | $19.6M | $80.0M | $275.7M | $41.7M |
RevenueNet incomeNet margin (right axis, %)
| Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $289.5M | $297.0M | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M | $321.2M |
| Growth (year over year) | +4.5% | +9.0% | +4.2% | +3.5% | −1.0% | −0.4% | −1.5% | +1.3% |
| Gross profit | $183.0M | $193.9M | $214.6M | $198.8M | $188.1M | $191.3M | $208.3M | $211.4M |
| Gross margin | 63.2% | 65.3% | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% | 65.8% |
| Operating income | $40.0M | $47.4M | $38.7M | −$23.9M | $47.7M | $54.5M | $75.5M | $74.3M |
| Operating margin | 13.8% | 16.0% | 12.2% | −7.5% | 16.6% | 18.4% | 24.2% | 23.1% |
| Net income | $33.6M | $34.9M | $22.6M | −$17.7M | $38.2M | $38.0M | $51.0M | $54.6M |
| Net margin | 11.6% | 11.7% | 7.1% | −5.6% | 13.3% | 12.8% | 16.4% | 17.0% |
| EPS (diluted) | $0.21 | $0.22 | $0.14 | −$0.11 | $0.24 | $0.24 | $0.32 | $0.36 |
| Balance sheet | ||||||||
| Cash and equivalents | $187.5M | $177.5M | $140.7M | $162.2M | $145.0M | $172.9M | $209.8M | $264.7M |
| Total assets | $2.74B | $2.67B | $2.64B | $2.56B | $2.53B | $2.52B | $2.55B | $2.59B |
| Total liabilities | $597.4M | $591.9M | $626.2M | $639.1M | $560.3M | $511.7M | $465.3M | $478.5M |
| Long-term debt | $300.0M | $300.0M | $330.0M | $346.0M | $300.0M | $260.0M | $200.0M | $200.0M |
| Shareholders' equity | $2.14B | $2.08B | $2.02B | $1.92B | $1.97B | $2.01B | $2.09B | $2.11B |
| Cash flow | ||||||||
| Operating cash flow | $63.9M | $84.3M | $41.1M | $98.2M | $27.6M | $82.4M | $86.7M | $95.4M |
| Capital expenditure | $9.17M | $6.82M | $10.1M | $4.89M | $5.36M | $5.92M | $9.09M | $8.48M |
| Free cash flow | $54.7M | $77.5M | $31.0M | $93.3M | $22.2M | $76.5M | $77.6M | $86.9M |
| Dividends paid | $12.7M | $12.7M | $12.6M | $12.4M | $12.4M | $12.5M | $12.5M | $12.5M |
| Share buybacks | — | — | $100.0M | $100.1M | $24.0K | $0 | $0 | $41.7M |
From Bio-Techne's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Bio-Techne
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Source: Wikipedia — Bio-Techne
- Headquarters
- Minneapolis, Minnesota From SEC filings, Oct 2026
Recent News (20)
-
SK Hynix shares plunge 10% amid Asia tech rout as Fed rate hike fears, AI funding worries mount A sell-off in global technology hardware stocks deepened Thursday.
-
Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough? Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough? Investor's Business Daily
-
Tech stock lead rout after US inflation fuels rate hike bets Tech stock lead rout after US inflation fuels rate hike bets Yahoo Finance Singapore
-
SK Hynix shares plunge 10% amid Asia tech rout as Fed rate hike fears, AI funding worries mount SK Hynix shares plunge 10% amid Asia tech rout as Fed rate hike fears, AI funding worries mount CNBC
-
The AI trade is splintering as inflation fears rattle hyped-up tech stocks Investors are wondering if steep inflation and increased borrowing costs could derail the AI buildout.
-
-
Oracle slumps 9% amid tech selloff, AI buildout concerns (ORCL:NYSE) Oracle slumps 9% amid tech selloff, AI buildout concerns (ORCL:NYSE) Seeking Alpha
-
Apple Hits $5 Trillion Milestone as Rest of Tech Trade Falters. Can It Hold? Apple Hits $5 Trillion Milestone as Rest of Tech Trade Falters. Can It Hold? Barron's
-
Dell Technologies tumbles 11% on Barclays downgrade, tech slide (DELL:NYSE) Dell Technologies tumbles 11% on Barclays downgrade, tech slide (DELL:NYSE) Seeking Alpha
-
-
Anduril employee tender offer would value the defense tech startup at $90 billion Anduril has been a major winner of the growing U.S. defense tech boom and President Donald Trump's plans to reindustrialize the U.S. military
-
-
-
Tech giants race to get AI gadgets on shelves for holiday rush With the holidays just a couple months away, tech companies are betting this is finally the year that AI gadgets make the shopping list.
-
-
-
-
-
-
More Health Care stocks
- RVTY Revvity
- SOLV Solventum
- STE Steris
- SYK Stryker Corporation
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group
- VEEV Veeva Systems